Press release
Neurofibrosarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Neurofibrosarcoma Pipeline Report to explore emerging therapies, key Neurofibrosarcoma Companies, and future Neurofibrosarcoma treatment landscapes @ Neurofibrosarcoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Neurofibrosarcoma Pipeline Report
* In April 2025, University of Florida conducted a phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
* In April 2025, Alexander Z. Wei, MD announced a phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.
* DelveInsight's Neurofibrosarcoma Ppipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Neurofibrosarcoma treatment.
* The leading Neurofibrosarcoma Companies such as Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
* Promising Neurofibrosarcoma Pipeline Therapies such as Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others.
Stay ahead with the most recent pipeline outlook for Neurofibrosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neurofibrosarcoma Treatment Drugs [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Neurofibrosarcoma Emerging Drugs Profile
* NFX-179: NFlection Therapeutics
NFX-179 is an investigational mitogen-activated protein kinase kinase (MEK) inhibitor. NFX-179 is a ""soft"" (metabolically labile) drug, which, when formulated as NFX-179 Gel for topical application, is designed to concentrate at the dermal site of action but degrade in systemic circulation, thereby significantly reducing side effects compared to systemically available MEK inhibitors.
* Sirolimus: Nobelpharma
Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus: FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.
The Neurofibrosarcoma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibrosarcoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibrosarcoma treatment.
* Neurofibrosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Neurofibrosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibrosarcoma market.
Explore groundbreaking therapies and clinical trials in the Neurofibrosarcoma Pipeline. Access DelveInsight's detailed report now! @ New Neurofibrosarcoma Drugs [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Neurofibrosarcoma Companies
Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
Neurofibrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
Neurofibrosarcoma Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Neurofibrosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Neurofibrosarcoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Neurofibrosarcoma Pipeline Report
* Coverage- Global
* Neurofibrosarcoma Companies- Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
* Neurofibrosarcoma Pipeline Therapies- Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others.
* Neurofibrosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Neurofibrosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Neurofibrosarcoma Drug development? Find out in DelveInsight's exclusive Neurofibrosarcoma Pipeline Report-access it now! @ Neurofibrosarcoma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Neurofibrosarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Neurofibrosarcoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Sirolimus: Nobelpharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ASTX727: Astex Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* MRTX1719: Mirati Therapeutics
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Neurofibrosarcoma Key Companies
* Neurofibrosarcoma Key Products
* Neurofibrosarcoma- Unmet Needs
* Neurofibrosarcoma- Market Drivers and Barriers
* Neurofibrosarcoma- Future Perspectives and Conclusion
* Neurofibrosarcoma Analyst Views
* Neurofibrosarcoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neurofibrosarcoma-pipeline-appears-robust-with-15-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neurofibrosarcoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibrosarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4006767 • Views: …
More Releases from ABNewswire
Dr. Zenovia Bryant-Bright Announces Upcoming Memoir: A Black Love Story of Loss, …
Image: https://www.abnewswire.com/upload/2026/01/45ff470dbcae7669354b6505319ce953.jpg
United States - Dr. Zenovia Bryant-Bright announces the release of her highly anticipated memoir, A Black Love Story of Loss, and Life After the Military , arriving January 26, 2026. This deeply personal and courageous book is more than a collection of memories, it is a testimony of survival, strength, love, and truth.
Too often, the stories of Black women who have served in the military are erased, dismissed, or…
GetInsuredTexas.com Launches as the Essential Guide to Texas Insurance Policies, …
GetInsuredTexas.com, a new website from Baxter Insurance Agency, Inc., is now live, offering a one-stop shop for Texans to navigate the complexities of the state's insurance market, from understanding policies to comparing companies.
HOUSTON, TX - Jan 11, 2026 - Baxter Insurance Agency, Inc., a trusted name in the Texas insurance industry for over 40 years, is proud to announce the launch of GetInsuredTexas.com. This new platform is designed to be…
AI and the Future of the Translation Profession - Translation Conference to Deli …
Want to work smarter with AI - not just "go with the flow"? At the conference we'll share tools, methods, and practical workflows from the field - not just theory. Upgrade your professional toolkit.
The 2026 ITA hybrid translation conference will focus on one of the most urgent needs of today's language professionals: practical, applicable knowledge for working effectively - and responsibly - with artificial intelligence in real-world translation environments.
While public…
Caliente Brands Brings Bold Heat to Premium Beef Jerky Market with Authentic Spi …
Caliente Brands, LLC launches CalienteJerky.com, offering hickory-smoked beef jerky crafted exclusively from 100% USDA Approved Beef with uniquely spicy flavor profiles. The veteran-owned company targets consumers seeking bold, adventurous snack options with flavors ranging from Spicy Peppered to innovative Spicy Birria, delivering what the brand promises: where smoky and spicy meet delicious.
Caliente Brands, LLC has officially entered the premium beef jerky market with a clear mission: to deliver authentic spicy…
More Releases for Neurofibrosarcoma
Neurofibrosarcoma Market Growing at a CAGR of around 6.3%
Neurofibrosarcoma Market
The Neurofibrosarcoma Market was valued at ~USD 420 million in 2024 and is projected to reach ~USD 780 million by 2034, growing at a CAGR of around 6.3%. Growth is driven by increasing diagnosis of peripheral nerve sheath tumors, rising incidence of neurofibromatosis-associated malignancies, and expanding use of advanced oncology therapies.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71264
Key Market Drivers
• Rising prevalence of malignant peripheral nerve sheath tumors (MPNSTs),…
Adult-onset Still Disease (AOSD) market growing at a CAGR of around 7.7%
The Adult-onset Still Disease (AOSD) market was valued at ~USD 1.2 billion in 2024 and is projected to reach ~USD 2.5 billion by 2034, growing at a CAGR of around 7.7%. Rising diagnosis rates, improved biomarker-based testing, and strong adoption of biologics are the primary growth drivers.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71305
Key Market Drivers
• Increasing awareness and improved identification of AOSD cases.
• Growing use of IL-1 and IL-6 inhibitors…
Hepatic Impairment Market Registering a CAGR of 4.5%-5.5% during the forecast pe …
Market Overview
The Hepatic Impairment market is growing steadily as the global burden of liver diseases increases, particularly cirrhosis, hepatitis, alcoholic liver disease, and drug-induced liver injury (DILI). Hepatic impairment affects drug metabolism, treatment selection, and patient outcomes, creating substantial demand for specialized diagnostics, monitoring tools, and supportive therapies.
The global hepatic impairment market was valued at USD 14-15 billion in 2024 and is projected to reach USD 20-22 billion by 2032,…
Neurofibrosarcoma Market Massive Growth opportunity Ahead
Introduction
Neurofibrosarcoma is a rare and aggressive form of cancer that arises from nerve sheath cells, often associated with the nerve fibers in the body. This type of soft tissue sarcoma typically occurs in patients with neurofibromatosis type 1 (NF1), a genetic disorder that predisposes individuals to tumors along the nerves. Neurofibrosarcoma is characterized by malignant tumors that form in or around the nerve fibers, commonly affecting the limbs, abdomen, thoracic…
Neurofibrosarcoma Treatment Market Size in 7MM is expected to grow at a decent C …
DelveInsight's "Neurofibrosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Neurofibrosarcoma, historical and forecasted epidemiology as well as the Neurofibrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Neurofibrosarcoma Market Share @ Neurofibrosarcoma Market Outlook- https://www.delveinsight.com/sample-request/neurofibrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Neurofibrosarcoma Market Report
• In February 2025, Adaptimmune announced a study to…
Neurofibrosarcoma Market Is Expected to Expand at a Healthy Growth Rate During t …
DelveInsight's "Neurofibrosarcoma Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neurofibrosarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
[https://www.delveinsight.com/report-store/neurofibrosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size…
